These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29343473)

  • 21. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.
    Fusco C; Andreone V; Coppola G; Luongo V; Guerini F; Pace E; Florio C; Pirozzi G; Lanzillo R; Ferrante P; Vivo P; Mini M; Macrì M; Orefice G; Lombardi ML
    Neurology; 2001 Dec; 57(11):1976-9. PubMed ID: 11739812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the safety of β-interferons in MS: A series of nested case-control studies.
    de Jong HJI; Kingwell E; Shirani A; Cohen Tervaert JW; Hupperts R; Zhao Y; Zhu F; Evans C; van der Kop ML; Traboulsee A; Gustafson P; Petkau J; Marrie RA; Tremlett H;
    Neurology; 2017 Jun; 88(24):2310-2320. PubMed ID: 28500224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
    J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of response to interferon therapy in multiple sclerosis.
    Sellebjerg F; Søndergaard HB; Koch-Henriksen N; Sørensen PS; Oturai AB
    Acta Neurol Scand; 2014 Oct; 130(4):268-75. PubMed ID: 24943672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
    Løken-Amsrud KI; Holmøy T; Bakke SJ; Beiske AG; Bjerve KS; Bjørnarå BT; Hovdal H; Lilleås F; Midgard R; Pedersen T; Benth JS; Sandvik L; Torkildsen O; Wergeland S; Myhr KM
    Neurology; 2012 Jul; 79(3):267-73. PubMed ID: 22700809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glypican 5 is an interferon-beta response gene: a replication study.
    Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
    Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
    Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
    Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    Newsome SD; Kieseier BC; Arnold DL; Shang S; Liu S; Hung S; Sabatella G
    J Neurol; 2016 Sep; 263(9):1778-87. PubMed ID: 27314959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of CYP27B1 gene expression in Iranian patients with relapsing-remitting multiple sclerosis.
    Rezaie Z; Taheri M; Kohan L; Sayad A
    Hum Antibodies; 2016; 24(3-4):71-76. PubMed ID: 27792005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OAS1: a multiple sclerosis susceptibility gene that influences disease severity.
    O'Brien M; Lonergan R; Costelloe L; O'Rourke K; Fletcher JM; Kinsella K; Sweeney C; Antonelli G; Mills KH; O'Farrelly C; Hutchinson M; Tubridy N
    Neurology; 2010 Aug; 75(5):411-8. PubMed ID: 20679634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
    Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
    J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.
    Mäurer M; Dachsel R; Domke S; Ries S; Reifschneider G; Friedrich A; Knorn P; Landefeld H; Niemczyk G; Schicklmaier P; Wernsdörfer C; Windhagen S; Albrecht H; Schwab S;
    Eur J Neurol; 2011 Aug; 18(8):1036-45. PubMed ID: 21199183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.